Lluis L Puig (Luis Puig, L Puig, Lluis Puig, L Puig Sanz, Luís Puig, Lluís Puig)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 128

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

The British journal of dermatology

International journal of molecular sciences

The Journal of dermatological treatment

Universitat Autònoma de Barcelona (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Universitat Autònoma de Barcelona

Spain

PHD

Publications

Andreas Pinter, Ahmed M Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Cong Bang Truong, Lluis L Puig, Mark Lebwohl
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study. Dermatology and therapy 14 (5) (2024)
Alexandra Alturo-Pons, Elena Carmona-Rocha, Lluís Rusiñol, Helena Iznardo, Lluis L Puig
Pustules, arthritis, and fever in a patient with Crohn's disease. International journal of dermatology 63 (6) (2024)
Lluís Rusiñol, Lluis L Puig
Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. International journal of molecular sciences 25 (2) (2024)
Lluis L Puig, Hideki Fujita, Diamant Thaçi, Min Zheng, Ana Cristina Hernandez Daly, Craig Leonardi, Mark G Lebwohl, Jonathan Barker
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search. Dermatology and therapy (2024)
Andreas Pinter, Ahmed M Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Cong Bang Truong, Lluis L Puig, Mark Lebwohl
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study. Dermatology and therapy 14 (5) (2024)
Lluís Rusiñol, Lluis L Puig
Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. International journal of molecular sciences 25 (2) (2024)
Laura L Mateu-Arrom, Lluis L Puig
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert review of clinical pharmacology 17 (4) (2024)
Lluis L Puig, Antonio Costanzo, Elke M G J de Jong, Tiago Torres, Richard B Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and therapy (2024)
Andrea Chiricozzi, Giulia Coscarella, Lluis L Puig, Ronald B Vender, Jensen Yeung, Y José Manuel Carrascosa, Stefano Piaserico, Paolo Gisondi, Charles Lynde, Paulo Ferreira, Pedro Mendes Bastos, Esteban Daudén, Luiz Leite, Joana Valerio, Elena Del Alcázar-Viladomiu, Eva Vilarrasa, Mar Llamas Velasco, Mario Alessandri-Bonetti, Francesco Messina, Manfredo Bruni, Eugenia Veronica Di Brizzi, Federica Ricceri, Alessia Nidegger, Jan Hugo, Asfandyar Mufti, Athina-Ioanna Daponte, Laetitia Teixeira, Anna Balato, Marco Romanelli, Francesca Prignano, Spyridon Gkalpakiotis, Curdin Conrad, Elizabeth Lazaridou, Natalia Rompoti, Alexander J Stratigos, Miguel Nogueira, Ketty Peris, Tiago Torres
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Lluís Rusiñol, Lluis L Puig
A Narrative Review of the IL-18 and IL-37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. International journal of molecular sciences 25 (15) (2024)
Alexandra Alturo-Pons, Elena Carmona-Rocha, Lluís Rusiñol, Helena Iznardo, Lluis L Puig
Pustules, arthritis, and fever in a patient with Crohn's disease. International journal of dermatology 63 (6) (2024)
Elena Carmona-Rocha, Lluís Rusiñol, Lluis L Puig
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics 16 (2) (2024)
Elena Carmona-Rocha, Lluís Rusiñol, Lluis L Puig
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics 16 (2) (2024)
Alexandra Alturo-Pons, Elena Carmona-Rocha, Lluís Rusiñol, Helena Iznardo, Lluis L Puig
Pustules, arthritis, and fever in a patient with Crohn's disease. International journal of dermatology (2024)
Daniela Kampel Stolnicki, Laura C Coates, Charlotte E Gollins, Sahil Koppikar, Lourdes Maria Perez-Chada, Lluis L Puig, Philip S Helliwell, Atul A Deodhar, Christopher T Ritchlin, Samuel T Hwang, Cláudia Goldenstein-Schainberg
Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. The Journal of rheumatology (2024)
Andreas Pinter, Ahmed M Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Cong Bang Truong, Lluis L Puig, Mark Lebwohl
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study. Dermatology and therapy (2024)
Laura L Mateu-Arrom, Lluis L Puig
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert review of clinical pharmacology 17 (4) (2024)
Laura L Mateu-Arrom, Lluis L Puig
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert review of clinical pharmacology (2024)
Lluís Rusiñol, Lluis L Puig
A Narrative Review of the IL-18 and IL-37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. International journal of molecular sciences 25 (15) (2024)
Lluís Rusiñol, Lluis L Puig
Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. International journal of molecular sciences 25 (2) (2024)
Alexandra Alturo-Pons, Elena Carmona-Rocha, Lluís Rusiñol, Helena Iznardo, Lluis L Puig
Pustules, arthritis, and fever in a patient with Crohn's disease. International journal of dermatology 63 (6) (2024)
Tiago Torres, N C Brembilla, R G Langley, R B Warren, D Thaçi, A G A Kolios, Jörg C Prinz, A Londono-Garcia, Alexander Nast, M Santin, D Goletti, M Abreu, P Spuls, W H Boehncke, Lluis L Puig
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Andreas Pinter, Ahmed M Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Cong Bang Truong, Lluis L Puig, Mark Lebwohl
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study. Dermatology and therapy 14 (5) (2024)
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis L Puig
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. The Journal of dermatological treatment 34 (1) (2023)
Lluís Rusiñol, Lluis L Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, Lluis L Puig
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient preference and adherence 17 (2023)
Laura L Mateu-Arrom, Lluis L Puig
Genetic and Epigenetic Mechanisms of Psoriasis. Genes 14 (8) (2023)
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis L Puig
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. The Journal of dermatological treatment (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis L Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Lluís Rusiñol, Lluis L Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Guillermo Sánchez-Rodríguez, Lluis L Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Antonio Costanzo, Mar Llamas Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera-Díaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluis L Puig, Y José Manuel Carrascosa
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Elena Carmona-Rocha, Lluis L Puig
Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy (2023)
Davide Geat, Paolo Gisondi, Martina Maurelli, Lluis L Puig, Carle Paul, Diamant Thaçi, Lars Iversen, Francesco Bellinato, Giampiero Girolomoni
Price variability of TNF-α inhibitor biosimilars among European countries. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2023)
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Alex Stratigos, Myrto Trakatelli, Lluis L Puig, null null
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Paolo Gisondi, Lluis L Puig, Marie Aleth Richard, Carle Paul, Tamar Nijsten, Charles Taïeb, Alex Stratigos, Myrto Trakatelli, Carmen Salavastru, null null
Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kilian Eyerich, J Krueger, M Stahle, Knut Schäkel, Curdin Conrad, A Armstrong, R Gniadecki, Lluis L Puig, T Scoble, N Williams
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Alvaro Gonzalez-Cantero, W H Boehncke, J De Sutter, J L Zamorano, J Lambert, Lluis L Puig
Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis L Puig
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. The British journal of dermatology 188 (2) (2023)
Davide Geat, Paolo Gisondi, Martina Maurelli, Lluis L Puig, Carle Paul, Diamant Thaçi, Lars Iversen, Francesco Bellinato, Giampiero Girolomoni
Price variability of TNF-α inhibitor biosimilars among European countries. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2023)
Davide Geat, Paolo Gisondi, Martina Maurelli, Lluis L Puig, Carle Paul, Diamant Thaçi, Lars Iversen, Francesco Bellinato, Giampiero Girolomoni
Price variability of TNF-α inhibitor biosimilars among European countries. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2023)
Lluis L Puig, E Daudén, M Cuervas-Mons, C Novella, C Guisado
Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: the SPRING study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Marie Aleth Richard, Pierre Wolkenstein, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Myrto Trakatelli, Lluis L Puig, Alex Stratigos, null null
Ethnicity and skin conditions in Europe: a large survey from the "Burden of Skin Diseases" EADV project. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis L Puig, Siew Eng Choon, A B Gottlieb, S Marrakchi, J C Prinz, R Romiti, Y Tada, D von Bredow, M Gooderham
Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis L Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Giampiero Girolomoni, Laura Savage, Paolo Gisondi, Åke Svensson, Emmanuel Mahé, Matthias Augustin, Lluis L Puig
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and therapy (2023)
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Myrto Trakatelli, Lluis L Puig, Alex Stratigos, null null
Public perception of dermatologists in Europe: Results from a population-based survey. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Alexander Egeberg, Lars Erik Kristensen, Lluis L Puig, Phoebe Rich, Saxon D Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. The Journal of dermatological treatment 34 (1) (2023)
Lluis L Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Lluis L Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Guillermo Sánchez-Rodríguez, Lluis L Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Lluis L Puig, Antonio Costanzo, Elke M G J de Jong, Tiago Torres, Richard B Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. American journal of clinical dermatology (2023)
Lluís Rusiñol, Lluis L Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Lluis L Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis L Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis L Puig
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. The British journal of dermatology 188 (2) (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis L Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Davide Geat, Paolo Gisondi, Martina Maurelli, Lluis L Puig, Carle Paul, Diamant Thaçi, Lars Iversen, Francesco Bellinato, Giampiero Girolomoni
Price variability of TNF-α inhibitor biosimilars among European countries. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Guillermo Sánchez-Rodríguez, Lluis L Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Ana Maria Lé, Lluis L Puig, Tiago Torres
Deucravacitinib for the Treatment of Psoriatic Disease. American journal of clinical dermatology 23 (6) (2022)
Lluis L Puig
Psoriasis treatment: no more room on the summit? The British journal of dermatology 187 (6) (2022)
Katie Bechman, Emma S Cook, Nick Dand, Zenas Zee Ngai Yiu, Teresa Tsakok, Freya Meynell, Bolaji Coker, Alexandra Vincent, Herve Bachelez, Ines Barbosa, Matthew A Brown, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jade Kelly, Jo Lydie Wilfried Lambert, Camille Lancelot, Sinéad M Langan, Kayleigh J Mason, Helen McAteer, Lucy Moorhead, Luigi Naldi, Katherine Jones, Lluis L Puig, Phyllis I Spuls, Tiago Torres, Dominic Urmston, Amber Vesty, Richard Bruce Warren, Hoseah Waweru, John Weinman, Christopher Ernest Maitland Griffiths, Jonathan N W N Barker, Catherine H Smith, James B Galloway, Satveer K Mahil, null null
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. The British journal of dermatology 187 (2) (2022)
Helena Iznardo, Lluis L Puig
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. International journal of molecular sciences 23 (16) (2022)
Andreas Pinter, Lluis L Puig, Knut Schäkel, Adam Reich, Shirin Zaheri, Antonio Costanzo, Tsen Fang Tsai, Saxon D Smith, Charles Lynde, Alan Brnabic, Catherine Reed, Julie Hill, Christopher Schuster, Elisabeth Riedl, Carle Paul
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Journal of the European Academy of Dermatology and Venereology : JEADV 36 (11) (2022)
Helena Iznardo, E Vilarrasa, E Roé, Lluis L Puig
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (8) (2022)
Lluis L Puig, Antonio Costanzo, Ernesto J Muñoz-Elías, Maria Jazra, Sven Wegner, Carle F Paul, Curdin Conrad
The biological basis of disease recurrence in psoriasis: a historical perspective and current models. The British journal of dermatology 186 (5) (2022)
Néboa Zozaya, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, Y José Manuel Carrascosa, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio J Garcia-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de Los Ríos Luna, Lluis L Puig, Sandra Ros, Álvaro HIdalgo-Vega
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert review of pharmacoeconomics & outcomes research 22 (6) (2022)
James G Krueger, Lluis L Puig, Diamant Thaҫi
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. American journal of clinical dermatology 23 (Suppl 1) (2022)
Kristian Reich, L Iversen, Lluis L Puig, J Lambert, Ulrich Mrowietz, K Kaplan Saday, R B Warren
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (8) (2022)
Silvia Vidal, Lluis L Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, Antonio-Manuel Velasco-Pastor
Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22 , 6740. International journal of molecular sciences 23 (5) (2022)
Marie Aleth Richard, C Paul, T Nijsten, Paolo Gisondi, C Salavastru, Charles Taïeb, M Trakatelli, Lluis L Puig, A Stratigos, null null
Prevalence of most common skin diseases in Europe: a population-based study. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (7) (2022)
Lluís Rusiñol, Gemma Camiña-Conforto, Lluis L Puig
Biologic treatment of psoriasis in oncologic patients. Expert opinion on biological therapy (2022)
Kim A Papp, M G Lebwohl, Lluis L Puig, M Ohtsuki, S Beissert, J Zeng, S Rubant, R Sinvhal, Y Zhao, A M Soliman, G Alperovich, C Leonardi
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. The British journal of dermatology (2021)
Victoria Amat-Samaranch, Eugènia Agut-Busquet, Eva Vilarrasa, Lluis L Puig
New perspectives on the treatment of hidradenitis suppurativa. Therapeutic advances in chronic disease 12 (2021)
Kristian Reich, Curdin Conrad, Lars Erik Kristensen, Saxon D Smith, Lluis L Puig, Phoebe Rich, Christophe Sapin, Thorsten Holzkaemper, Uffe Koppelhus, Christopher Schuster
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. The Journal of dermatological treatment (2021)
Helena Iznardo, E Vilarrasa, Anna López-Ferrer, Lluis L Puig
Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. The British journal of dermatology 185 (3) (2021)
Mark Lebwohl, Ahmed M Soliman, Hongbo Yang, Jessie Wang, Jonathan Freimark, Lluis L Puig
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis. The Journal of dermatological treatment (2021)
S K Mahil, M Yates, S M Langan, Z Z N Yiu, T Tsakok, N Dand, Kayleigh J Mason, H McAteer, F Meynell, B Coker, A Vincent, D Urmston, A Vesty, J Kelly, C Lancelot, L Moorhead, Herve Bachelez, I N Bruce, Francesca Capon, C R Contreras, A P Cope, C De La Cruz, Paola Di Meglio, Paolo Gisondi, K Hyrich, D Jullien, J Lambert, H Marzo-Ortega, I McInnes, L Naldi, S Norton, Lluis L Puig, R Sengupta, P Spuls, Tiago Torres, R B Warren, H Waweru, J Weinman, C E M Griffiths, J N Barker, M A Brown, J B Galloway, C H Smith, null null
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. The British journal of dermatology 185 (1) (2021)
Andrew Blauvelt, M Ramharter, A D Cohen, W Xu, H Patel, C Schuster, E Riedl, Lluis L Puig
An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (11) (2021)
Helena Iznardo, Lluis L Puig
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. International journal of molecular sciences 22 (9) (2021)
Carla Tubau, Lluis L Puig
IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy 13 (4) (2021)
Kristian Reich, J B Hansen, Lluis L Puig, Maria-Polina Konstantinou, R B Warren
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
Jennifer Beecker, Kim A Papp, J Dutz, Ronald B Vender, Robert Gniadecki, Curtis L Cooper, Paolo Gisondi, Melinda J Gooderham, C H Hong, M G Kirchhof, C W Lynde, C Maari, Y Poulin, Lluis L Puig
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (4) (2021)
Silvia Vidal, Lluis L Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, Antonio-Manuel Velasco-Pastor
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. International journal of molecular sciences 22 (13) (2021)
Jo Lambert, Jes Birger Hansen, Anne Sohrt, Lluis L Puig
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and therapy 11 (4) (2021)
Helena Iznardo, Lluis L Puig
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert review of clinical immunology 17 (2) (2021)
Helena Iznardo, Lluis L Puig
Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic advances in chronic disease 12 (2021)
Cristina Garcia-Melendo, Xavier Cubiró, C López-Sánchez, M Turienzo, A Mozos, Lluis L Puig
Saprochaete capitata disseminated infection presenting as macular rash after haematopoietic stem cell transplantation. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (11) (2020)
Lluis L Puig, T-F Tsai, T Bhutani, J Uy, P Ramachandran, M Song, Y You, M Gooderham, M Lebwohl
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)
G Carretero, Y José Manuel Carrascosa, Lluis L Puig, J L Sánchez-Carazo, A López-Ferrer, P Cueva, C Soria, Raquel Rivera-Díaz, Isabel Belinchón-Romero, null null
Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Miguel Nogueira, Lluis L Puig, Tiago Torres
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs 80 (4) (2020)
Victoria Amat-Samaranch, Lluis L Puig
Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert opinion on drug safety 19 (4) (2020)
Jaime Piquero-Casals, Laura Martinez-Martinez, Agustín Alomar, Eduardo Rozas-Muñoz, Candido Juarez, Lluis L Puig
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation. Experimental dermatology 30 (3) (2020)
Lluis L Puig
The safety of ixekizumab in psoriasis drug therapy. Expert opinion on drug safety 19 (2) (2020)
Lluis L Puig
Head-to-head comparison of biologics in psoriasis: better acceleration does not necessarily win all races. The British journal of dermatology 184 (6) (2020)
Cristina López-Sánchez, Lluis L Puig
Guselkumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy 12 (6) (2020)
Tiago Torres, Lluis L Puig
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. American journal of clinical dermatology 21 (3) (2020)
R B Warren, J B Hansen, Kristian Reich, C Paul, Lluis L Puig
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Xavier Cubiró, Eduardo Rozas-Muñoz, Pau Castel, Esther Roé Crespo, Cristina Garcia-Melendo, Lluis L Puig, Eulalia Baselga
Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. Pediatric dermatology 37 (5) (2020)
Victoria Lucia Dávila Osorio, Helena Iznardo, Esther Roé, Lluis L Puig, Eulalia Baselga
Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatric dermatology 37 (4) (2020)

Lluis L Puig.css-eqlu8i{font-size:small;padding-left:4px;} (Luis Puig, L Puig, Lluis Puig, L Puig Sanz, Luís Puig, Lluís Puig)

Publication Activity (10 Years)

Top Topics

Top Venues

Lluis L Puig (Luis Puig, L Puig, Lluis Puig, L Puig Sanz, Luís Puig, Lluís Puig)